Marinomed Sees Sales of Virus-Blocking Nasal Spray Drop To Pre-Pandemic Levels

A "pandemic overhang" is impacting sales of Marinomed's virus-blocking nasal spray platform, Carragelose, which remains under strategic review by the company.

Nasal spray nose
• Source: Shutterstock

Austrian biotech Marinomed said sales of its virus-blocking compound Carragelose had slumped to pre-pandemic levels as a three-year period of elevated demand came to an end.

“After SARS-CoV-2-driven record sales in the last years, the market is now suffering a pandemic overhang with high customer stock levels and the return of the typical volatile seasonality,” commented CEO Andreas Grassauer

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Earnings

Looming Tariffs Give Boost To Latest PCH Results While Cutting Costs In Response Takes Priority

 

Looming imposition of tariffs by Trump on imports from most every country had an influence on consumers during the January-March period, particularly on online shopping. Increasing product prices on the table, “but our efforts are going to start with cost savings,” says CFO Christine Sacco.

Danes Get OTC Access To ED Treatment

 
• By 

Navamedic has launched Eroxon in Danish pharmacies giving men in the country OTC access to an ED treatment for the first time.

Perrigo Sees Growth Opportunities In Tariff Storm

 

As largest provider of private label/store brand OTCs with “100 plus molecules across 100% price point coverage,” CEO Patrick Lockwood-Taylor says Perrigo’s in position to capitalize as consumers become “more cautious” and look for lower-priced products.

Haleon Targets Low Income Households In Push To Reach 1bn More Consumers

 
• By 

Haleon wants to reach one billion more consumers by 2030 and plans to do this by tailoring products to those outside the highest income bracket. The UK-based firm's five-year growth plan will also see it generate £0.8bn in productivity savings.

More from Business

People On The Move: Appointments At Haleon, Wellnex, Orkla

 
• By 

A round-up of the latest consumer health leadership changes: Haleon names Middle East & Africa unit manager; Wellnex Life appoints interim chair; Orkla Health appoints CEO.

Opella Goes Solo Promising To ‘Redefine The Future Of Self-Care’

 
• By 

Private equity firm CD&R takes control of Opella while Sanofi retains a sizeable stake and nets €10bn.

PharmaSGP Targets More Of The Same As It Outperforms OTC Market

 
• By 

Germany-based firm grew three-times faster than the OTC pharmacy market in 2024 and is hoping to continue this momentum in 2025.